Small-cap pharma company Ajanta Pharma has surprised investors with a major announcement alongside its Q2 FY26 results. The company has declared a 1400% interim dividend, meaning shareholders will receive ₹28 per share on a face value of ₹2.
In total, the dividend payout amounts to nearly ₹350 crore.
Ajanta Pharma Dividend Details
The company has set Monday, 10 November 2025, as the record date for this interim dividend.
Investors holding Ajanta Pharma shares in their demat accounts on or before this date will receive ₹28 per share.
Dividend payment will be made on or after 20 November 2025.
Strong Q2 FY26 Results
Ajanta Pharma delivered solid financial performance in the September quarter.
- Revenue: ₹1,354 crore (Up 14% YoY; Q2 FY25: ₹1,187 crore)
- EBITDA: ₹328 crore (Up 5% YoY)
- EBITDA Margin: 24%
- Net Profit (PAT): ₹260 crore (Up 20% YoY; Q2 FY25: ₹216 crore)
However, the company incurred a mark-to-market forex loss of ₹41 crore this quarter.
Excluding this impact:
- EBITDA would have been: ₹369 crore (Up 9%)
- EBITDA Margin: 27%
- PAT Growth: 23% with a 22% margin
This shows that Ajanta Pharma’s operational performance remains strong, and profits grew robustly despite forex volatility.
Ajanta Pharma’s Stock History
Ajanta Pharma is part of the BSE 500 Index and has a market cap of ₹31,071 crore.
Over the last five years, its stock has delivered more than 131% returns, showcasing consistent growth.
Currently, the stock trades around ₹2,500.
In the past year, its 52-week high was ₹3,147.90, and the 52-week low was ₹2,022.05, demonstrating strong investor confidence and stable movement within a healthy range.
Dividend and Bonus Track Record
Ajanta Pharma is known for consistently rewarding its shareholders.
Previous dividends include:
- ₹28 per share on 6 November 2024
- ₹26 per share on 8 February 2024
- ₹10 and ₹15 per share on 4 August 2023
The company has also issued bonus shares twice in a 1:2 ratio:
- 22 June 2022
- 17 September 2013
This means shareholders received one bonus share for every two shares held.
This strong reward history confirms the company’s shareholder-friendly approach.
Will the Stock Rise After This Dividend?
Ajanta Pharma’s quarterly results, combined with the announcement of a 1400% interim dividend, are highly attractive signals for investors.
Strong revenue growth, rising profit, and a consistent dividend policy all highlight the company’s solid financial health.
The big question now is — Will Ajanta Pharma’s stock climb to new highs after this record dividend, or has the market already priced it in?
2 thoughts on “Ajanta Pharma’s Big Announcement: Massive 1400% Interim Dividend for Shareholders, Record Date Finalized”